Vilin Bio Med

Which are the latest news on Vilin Bio Med?

Why is Vilin Bio Med Ltd falling/rising?

As of 05-Sep, Vilin Bio Med Ltd's stock price is rising to Rs 54.25, up 4.93%. This increase is driven by strong performance metrics, including a 21.36% rise over the past week and a year-to-date gain of 158.95%, alongside increased investor interest and positive technical indicators.

As of 05-Sep, Vilin Bio Med Ltd's stock price is rising, currently at Rs 54.25, reflecting a change of Rs 2.55 or 4.93%. This upward movement can be attributed to several factors. Over the past week, the stock has increased by 21.36%, significantly outperforming the Sensex, which has declined by 1.15%. Similarly, in the past month, the stock has risen by 25.87%, while the Sensex has fallen by 2.91%. Year-to-date, Vilin Bio Med has shown an impressive gain of 158.95%, compared to the Sensex's decline of 8.54%.<BR><BR>Additionally, the stock is trading close to its 52-week high, just 0.28% away from Rs 54.4, indicating strong upward momentum. Today's performance has also outperformed its sector by 5.38%. The stock is trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which is a positive technical indicator. Furthermore, there has been a notable increase in investor participation, with delivery volume rising by 94.44% against the 5-day average. This suggests heightened interest and confidence among investors, contributing to the stock's rise. Overall, these factors collectively explain the upward trend in Vilin Bio Med Ltd's stock price.

What does Vilin Bio Med do?

Vilin Bio Med Ltd is a micro-cap pharmaceutical and biotechnology company focused on producing therapeutic drugs, with a market cap of INR 68 Cr. It has no recent sales or profit data, and key financial metrics include a P/E ratio of 37.00 and a return on equity of 6.80%.

Overview:<BR>Vilin Bio Med Ltd is a micro-cap company operating in the Pharmaceuticals & Biotechnology industry, focusing on the production of various therapeutic drugs.<BR><BR>History:<BR>Vilin Bio Med Limited was incorporated on June 29, 2005, and commenced business on July 11, 2005. The company began its first commercial production in 2006 and expanded its facilities in 2007. As of now, there is no recent sales or profit data reported.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: INR 68 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 37.00<BR>Industry P/E: 37<BR>Dividend Yield: 0.00%<BR>Debt-Equity: -0.04<BR>Return on Equity: 6.80%<BR>Price to Book: 2.40<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Who are the peers of the Vilin Bio Med?

Vilin Bio Med's peers include Vineet Laborator, Zenith Drugs, Ajooni Biotech, and others. Vilin Bio Med has the highest 1-year return at 74.35%, while Zenith Drugs has the lowest at -38.58%.

Peers: The peers of Vilin Bio Med are Vineet Laborator, Zenith Drugs, Ajooni Biotech, Biofil Chemicals, Mangalam Drugs, Phaarmasia, Source Natural, Bharat Immunolog, Shelter Pharma, and Vasundhara Rasy.<BR><BR>Quality Snapshot: Below Average management risk is observed at Vineet Laborator, Zenith Drugs, Mangalam Drugs, Bharat Immunolog, and Phaarmasia, while Average management risk is found at Biofil Chemicals and Shelter Pharma. Good growth is noted at Ajooni Biotech and Shelter Pharma, while Average growth is seen at Vilin Bio Med and Phaarmasia, and Below Average growth is present at Vineet Laborator, Zenith Drugs, Biofil Chemicals, Mangalam Drugs, and Bharat Immunolog. Good capital structure is exhibited by Ajooni Biotech and Source Natural, while Average capital structure is found at Biofil Chemicals and Shelter Pharma, and Below Average capital structure is noted at Vineet Laborator, Zenith Drugs, Vilin Bio Med, Mangalam Drugs, Phaarmasia, Bharat Immunolog, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Vilin Bio Med at 74.35%, while the lowest is Zenith Drugs at -38.58%. Vilin Bio Med's return is significantly higher than all its peers. Additionally, the six-month return is negative for Zenith Drugs, Ajooni Biotech, Biofil Chemicals, Mangalam Drugs, and Bharat Immunolog.

How big is Vilin Bio Med?

As of 31st August, Vilin Bio Med Ltd has a market capitalization of 68.00 Cr, classifying it as a Micro Cap company, with Shareholder's Funds of 23.06 Cr and Total Assets of 27.73 Cr as of March 2025. There is no valid financial data available for net sales or net profit for the latest four quarters.

As of 31st August, <BR><BR>Market Cap: Vilin Bio Med Ltd has a market capitalization of 68.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for net sales or net profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: The latest reporting period is March 2025, with Shareholder's Funds amounting to 23.06 Cr and Total Assets of 27.73 Cr.

How has been the historical performance of Vilin Bio Med?

Vilin Bio Med's historical performance shows fluctuating sales growth, peaking at INR 15.80 crore in March 2024, but facing rising raw material costs and declining profits, with net profit after tax dropping to INR 0.22 crore by March 2025. Despite a decrease in total liabilities, the company has struggled with negative cash flow from operations.

Answer:<BR>The historical performance of Vilin Bio Med shows a fluctuating trend in key financial metrics over the past five years.<BR><BR>Breakdown:<BR>Vilin Bio Med's net sales have shown a general increase from INR 11.21 crore in March 2022 to INR 15.80 crore in March 2024, before slightly declining to INR 14.81 crore in March 2025. The total operating income followed a similar trend, peaking in March 2024. However, the raw material costs have risen significantly, from INR 9.06 crore in March 2021 to INR 13.47 crore in March 2025, impacting the operating profit, which decreased from INR 2.59 crore in March 2023 to INR 1.25 crore in March 2025. Profit before tax also declined from INR 1.78 crore in March 2023 to INR 0.31 crore in March 2025, while profit after tax dropped from INR 1.25 crore in March 2023 to INR 0.22 crore in March 2025. The company's total liabilities decreased from INR 32.40 crore in March 2024 to INR 27.73 crore in March 2025, with a notable reduction in short-term borrowings. Cash flow from operating activities has remained negative, with a net cash outflow of INR 5 crore in March 2025. Overall, while Vilin Bio Med has seen growth in sales and income, rising costs and declining profits indicate challenges in maintaining profitability.

Is Vilin Bio Med overvalued or undervalued?

As of September 23, 2025, Vilin Bio Med is considered very expensive with a PE ratio of 35.50, significantly higher than peers like Sun Pharma and Cipla, despite outperforming the Sensex with a 41.27% return over the past year.

As of 23 September 2025, the valuation grade for Vilin Bio Med has moved from expensive to very expensive, indicating a significant increase in perceived overvaluation. The company is currently assessed as overvalued, with a PE ratio of 35.50, an EV to EBIT of 38.02, and a PEG ratio of 0.95. These metrics suggest that the stock is trading at a premium compared to its earnings growth potential.<BR><BR>In comparison to its peers, Vilin Bio Med's PE ratio is higher than Sun Pharma's 34.11 and significantly above Cipla's more attractive 22.93. Additionally, while Divi's Lab shows a very expensive valuation with a PE of 69.64, it highlights the disparity within the sector. Notably, Vilin Bio Med has outperformed the Sensex over the past year with a return of 41.27%, contrasting with the Sensex's decline of 2.97%. This performance, however, does not mitigate the concerns regarding its current valuation levels.

Who are the top shareholders of the Vilin Bio Med?

The top shareholders of Vilin Bio Med are Venkata Bhagi Rao Sadhanala with 32.79%, followed by public shareholder Percy Homi Italia at 4.29%, and individual investors holding a total of 34.18%. There are no holdings by mutual funds or foreign institutional investors.

The top shareholders of Vilin Bio Med include the promoters, with Venkata Bhagi Rao Sadhanala holding the largest share at 32.79%. The highest public shareholder is Percy Homi Italia, who owns 4.29%. Additionally, individual investors collectively hold 34.18% of the company's shares. There are currently no holdings by mutual funds or foreign institutional investors (FIIs).

What is the technical trend for Vilin Bio Med?

As of June 3, 2025, Vilin Bio Med's technical trend is mildly bullish, supported by a bullish weekly MACD and Bollinger Bands, despite bearish signals from the RSI and Dow Theory.

As of 3 June 2025, the technical trend for Vilin Bio Med has changed from bullish to mildly bullish. The weekly MACD remains bullish, while the RSI is bearish, indicating some weakness in momentum. The Bollinger Bands are bullish on both weekly and monthly time frames, supporting the mildly bullish stance. Daily moving averages are also bullish, suggesting short-term strength. However, Dow Theory indicates bearish trends on both weekly and monthly levels, which could be a concern. The On-Balance Volume (OBV) shows a mildly bullish signal weekly but is mildly bearish monthly, adding to the mixed signals. Overall, the current technical stance is mildly bullish, driven primarily by the weekly MACD and Bollinger Bands, despite bearish signals from the RSI and Dow Theory.

When is the next results date for Vilin Bio Med?

No Upcoming Board Meetings

Has Vilin Bio Med declared dividend?

No Dividend History Available